CONtinuous Subcutaneous Insulin Infusion STudy ENrolling Type 1 (CONSISTENT 1) : Evaluation of Metabolic Outcomes and Safety of Hylenex Recombinant (Hyaluronidase Human Injection) Used as a Preadministration Infusion Site Treatment in Subjects With Type 1 Diabetes (T1DM) Using Continuous Subcutaneous Insulin Infusion (CSII)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Hyaluronidase (Primary) ; Insulin
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CONSISTENT 1
- Sponsors Halozyme Therapeutics
- 28 Oct 2014 Secondary endpoints, inclusion exclusion criteria and treatment table modified according to ClinicalTrials.gov record.
- 18 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 12 May 2014 Halozyme Therapeutics plans to present additional data from this study at the 74th Scientific Sessions of the American Diabetes Association (ADA) being held in San Francisco from 13-17 June 2014.